175 research outputs found
Rapid and MR-Independent IK1 activation by aldosterone during ischemia-reperfusion
In ST elevation myocardial infarction (STEMI) context, clinical studies have shown the deleterious
effect of high aldosterone levels on ventricular arrhythmia occurrence and cardiac
mortality. Previous in vitro reports showed that during ischemia-reperfusion, aldosterone
modulates K+ currents involved in the holding of the resting membrane potential (RMP).
The aim of this study was to assess the electrophysiological impact of aldosterone on IK1
current during myocardial ischemia-reperfusion. We used an in vitro model of “border zone”
using right rabbit ventricle and standard microelectrode technique followed by cell-attached
recordings from freshly isolated rabbit ventricular cardiomyocytes. In microelectrode experiments,
aldosterone (10 and 100 nmol/L, n=7 respectively) increased the action potential
duration (APD) dispersion at 90% between ischemic and normoxic zones (from 95±4ms to
116±6 ms and 127±5 ms respectively, P<0.05) and reperfusion-induced sustained premature
ventricular contractions occurrence (from 2/12 to 5/7 preparations, P<0.05). Conversely,
potassium canrenoate 100 nmol/L and RU 28318 1 μmol/l alone did not affect AP
parameters and premature ventricular contractions occurrence (except Vmax which was
decreased by potassium canrenoate during simulated-ischemia). Furthermore, aldosterone
induced a RMP hyperpolarization, evoking an implication of a K+ current involved in the
holding of the RMP. Cell-attached recordings showed that aldosterone 10 nmol/L quickly
activated (within 6.2±0.4 min) a 30 pS K+-selective current, inward rectifier, with pharmacological
and biophysical properties consistent with the IK1 current (NPo =1.9±0.4 in control vs
NPo=3.0±0.4, n=10, P<0.05). These deleterious effects persisted in presence of RU 28318,
a specific MR antagonist, and were successfully prevented by potassium canrenoate, a non
specific MR antagonist, in both microelectrode and patch-clamp recordings, thus indicating
a MR-independent IK1 activation. In this ischemia-reperfusion context, aldosterone induced
rapid and MR-independent deleterious effects including an arrhythmia substrate (increased
APD90 dispersion) and triggered activities (increased premature ventricular contractions
occurrence on reperfusion) possibly related to direct IK1 activation
Numerical model of the temperature dependence of the up-conversion efficiency of fluoride crystals codoped with ytterbium and thulium
We review the role of temperature on the up-conversion efficiency of materials that are good candidates to be used as the three primary-color emitters in optically written displays. A rate equation model is given for the blue emitting material that includes temperature-dependent coefficients for energy transfer and cross relaxation. Increased temperature leads to decreased up-conversion efficiency. The effect of pumping conditions on heating the emitting material is illustrated and explained. Steps to reduce the temperature rise when pumping up-conversion materials are described
Primary aldosteronism: A Japanese perspective
Primary aldosteronism (PA) is the most common cause of secondary hypertension, accounting for 10% of all hypertension. Far from being benign, hypertension due to PA is associated with high cardiovascular morbidity and mortality. However, PA is still underdiagnosed in general practice. Recent reports strongly recommend that identifying patients with PA is cost-beneficial based on improved cardiovascular outcomes afforded by specific surgical and medical treatment. This review provides an update of PA including controversial aspects of diagnosis and treatment
A new surgical technique of uterine auto-transplantation in cynomolgus monkey: preliminary report about two cases
Device complications with addition of defibrillation to cardiac resynchronisation therapy for primary prevention
Objective: In patients indicated for cardiac resynchronisation therapy (CRT), the choice between a CRT-pacemaker (CRT-P) versus defibrillator (CRT-D) remains controversial and indications in this setting have not been well delineated. Apart from inappropriate therapies, which are inherent to the presence of a defibrillator, whether adding defibrillator to CRT in the primary prevention setting impacts risk of other acute and late device-related complications has not been well studied and may bear relevance for device selection. //
Methods: Observational multicentre European cohort study of 3008 consecutive patients with ischaemic or non-ischaemic dilated cardiomyopathy and no history of sustained ventricular arrhythmias, undergoing CRT implantation with (CRT-D, n=1785) or without (CRT-P, n=1223) defibrillator. Using propensity score and competing risk analyses, we assessed the risk of significant device-related complications requiring surgical reintervention. Inappropriate shocks were not considered except those due to lead malfunction requiring lead revision. //
Results: Acute complications occurred in 148 patients (4.9%), without significant difference between groups, even after considering potential confounders (OR=1.20, 95% CI 0.72 to 2.00, p=0.47). During a mean follow-up of 41.4±29 months, late complications occurred in 475 patients, giving an annual incidence rate of 26 (95% CI 9 to 43) and 15 (95% CI 6 to 24) per 1000 patient-years in CRT-D and CRT-P patients, respectively. CRT-D was independently associated with increased occurrence of late complications (HR=1.68, 95% CI 1.27 to 2.23, p=0.001). In particular, when compared with CRT-P, CRT-D was associated with an increased risk of device-related infection (HR 2.10, 95% CI 1.18 to 3.45, p=0.004). Acute complications did not predict overall late complications, but predicted device-related infection (HR 2.85, 95% CI 1.71 to 4.56, p<0.001). //
Conclusions: Compared with CRT-P, CRT-D is associated with a similar risk of periprocedural complications but increased risk of long-term complications, mainly infection. This needs to be considered in the decision of implanting CRT with or without a defibrillator
Vitamin D supplementation for the prevention of type 2 diabetes in overweight adults: study protocol for a randomized controlled trial
Despite Australia's sunny climate, low vitamin D levels are increasingly prevalent. Sun exposure is limited by long working hours, an increase in time spent indoors, and sun protection practices, and there is limited dietary vitamin D fortification. While the importance of vitamin D for bone mineralization is well known, its role as a protective agent against chronic diseases, such as type 2 diabetes and cardiovascular disease, is less understood. Observational and limited intervention studies suggest that vitamin D might improve insulin sensitivity and secretion, mainly via its anti-inflammatory properties, thereby decreasing the risk of development and progression of type 2 diabetes. The primary aim of this trial is to investigate whether improved plasma concentrations of 25-hydroxyvitamin D (25(OH)D), obtained through vitamin D supplementation, will increase insulin sensitivity and insulin secretion. A secondary aim is to determine whether these relationships are mediated by a reduction in underlying subclinical inflammation associated with obesity.Fifty overweight but otherwise healthy nondiabetic adults between 18 and 60 years old, with low vitamin D levels (25(OH)D < 50 nmol/l), will be randomly assigned to intervention or placebo. At baseline, participants will undergo a medical review and anthropometric measurements, including dual X-ray absorptiometry, an intravenous glucose tolerance test, muscle and fat biopsies, a hyperinsulinemic euglycemic clamp, and questionnaires assessing diet, physical activity, sun exposure, back and knee pain, and depression. The intervention group will receive a first dose of 100,000 IU followed by 4,000 IU vitamin D (cholecalciferol) daily, while the placebo group will receive apparently identical capsules, both for a period of 16 weeks. All measurements will be repeated at follow-up, with the primary outcome measure expressed as a change from baseline in insulin sensitivity and secretion for the intervention group compared with the placebo group. Secondary outcome measures will compare changes in anthropometry, cardiovascular risk factors, and inflammatory markers.The trial will provide much needed clinical evidence on the impact of vitamin D supplementation on insulin resistance and secretion and its underlying mechanisms, which are relevant for the prevention and management of type 2 diabetes.Clinicaltrials.gov ID: NCT02112721 .Barbora de Courten, Aya Mousa, Negar Naderpoor, Helena Teede, Maximilian P J de Courten and Robert Scrag
One life ends, another begins: Management of a brain-dead pregnant mother - A systematic review -
Background: An accident or a catastrophic disease may occasionally lead to brain death (BD) during pregnancy. Management of brain-dead pregnant patients needs to follow special strategies to support the mother in a way that she can deliver a viable and healthy child and, whenever possible, also be an organ donor. This review discusses the management of brain-dead mothers and gives an overview of recommendations concerning the organ supporting therapy. Methods: To obtain information on brain-dead pregnant women, we performed a systematic review of Medline, EMBASE and the Cochrane Central Register of Controlled Trials (CENTRAL). The collected data included the age of the mother, the cause of brain death, maternal medical complications, gestational age at BD, duration of extended life support, gestational age at delivery, indication of delivery, neonatal outcome, organ donation of the mothers and patient and graft outcome. Results: In our search of the literature, we found 30 cases reported between1982 and 2010. A nontraumatic brain injury was the cause of BD in 26 of 30 mothers. The maternal mean age at the time of BD was 26.5 years. The mean gestational age at the time of BD and the mean gestational age at delivery were 22 and 29.5 weeks, respectively. Twelve viable infants were born and survived the neonatal period. Conclusion: The management of a brain-dead pregnant woman requires a multidisciplinary team which should follow available standards, guidelines and recommendations both for a nontraumatic therapy of the fetus and for an organ-preserving treatment of the potential donor
- …